HUTCHMED
About: HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Employees: 1,811
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
2.73% more ownership
Funds ownership: 0.76% [Q1] → 3.48% (+2.73%) [Q2]
0% more funds holding
Funds holding: 62 [Q1] → 62 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
8% less capital invested
Capital invested by funds: $99.6M [Q1] → $91.4M (-$8.21M) [Q2]
14% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 21
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $73K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
B of A Securities
Dimple Gosai
|
$28
|
Buy
Maintained
|
22 Jul 2025 |
Financial journalist opinion
Based on 5 articles about HCM published over the past 30 days
